Bullish & Foolish
Full LUCD fundamentals All 466 on the Survival Watch

LUCDLucid Diagnostics Inc.

Is Lucid Diagnostics struggling financially?

Yes, by its own account. Lucid Diagnostics told the SEC on 13 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

14/100

Critical

Sector
Biotech/Pharma
Market cap
$196.0M
Source filing
10-Q 13 May 2026
Balance sheet
30 Jun 2026

Cash runway

Not estimable

The latest filings do not carry the cash or cash-flow lines needed to estimate a runway. Publishing a number here would mean inventing one.

What it reported

Cash burned over the last 12 months

$46.7M

What Lucid Diagnostics told the SEC

…date to determine whether it is probable an entity will not meet its financial obligations within one year from the financial statement issuance date. Substantial doubt about an entity’s ability to continue as a going concern exists when conditions and events, considered in the aggregate, indicate it is probable the entity will be unable to meet its financial obligations as they become due within one year…

Lucid Diagnostics Inc., Form 10-Q, filed 13 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 92.6% share-count increase The company issued stock. Each share now owns 48.1% less of the business than a year ago, before any change in the price.
  • Debt pressure is material Operating earnings cover only -6335.5x the interest bill, so the interest is being met out of cash reserves rather than out of the business.
  • Cash burn is narrowing It is spending 42% less cash per year than it was, so the runway above is lengthening rather than shortening.

Other Biotech/Pharma companies that filed the doubt